Evaluation of Retinal Structure With High Resolution Optical Coherence Tomography (OCT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by University Hospital Inselspital, Berne
Sponsor:
Collaborator:
University of Bern
Information provided by (Responsible Party):
Sebastian Wolf, University Hospital Inselspital, Berne
ClinicalTrials.gov Identifier:
NCT00564291
First received: November 26, 2007
Last updated: June 24, 2014
Last verified: June 2014
  Purpose

Comparison of different OCT instruments to assess retinal thickness, correlation to fluorescein angiography, and visual outcome after therapy with anti-VEGF therapy


Condition
Macular Edema
CNV

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Evaluation of Retinal Structure With High Resolution OCT

Resource links provided by NLM:


Further study details as provided by University Hospital Inselspital, Berne:

Primary Outcome Measures:
  • Integrity of retinal layers [ Time Frame: End of study ] [ Designated as safety issue: No ]

Estimated Enrollment: 700
Study Start Date: January 2007
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Healthy volunteers
2
CSME secondary to diabetic retinopathy
3
ARMD with CNV before and after therapy
4
ARMD atrophic
5
Retinal vein occlusion
6
retinitis pigmentosa
7
vitreoretinal proliferation

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

healthy subjects and patients with macular diseases

Criteria

Inclusion Criteria:

  • Macular disease
  • Healthy subjects
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00564291

Contacts
Contact: Ute Wolf-Schnurrbusch, MD ute.wolf@insel.ch

Locations
Switzerland
Klinik und Poliklinik für Augenheilkunde, University Bern Recruiting
Bern, Switzerland
Principal Investigator: Ute Wolf-Schnurrbusch, MD         
Sponsors and Collaborators
Sebastian Wolf
University of Bern
Investigators
Principal Investigator: Ute Wolf-Schnurrbusch, MD University of Bern
Study Director: Sebastian Wolf, MD PhD University of Bern
  More Information

No publications provided by University Hospital Inselspital, Berne

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Sebastian Wolf, Director, University Hospital Inselspital, Berne
ClinicalTrials.gov Identifier: NCT00564291     History of Changes
Other Study ID Numbers: KEK 044/07
Study First Received: November 26, 2007
Last Updated: June 24, 2014
Health Authority: Switzerland: Ethikkommission

Keywords provided by University Hospital Inselspital, Berne:
OCT

Additional relevant MeSH terms:
Edema
Macular Edema
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases

ClinicalTrials.gov processed this record on July 24, 2014